Brief: Innovent Biologics Says Mazdutide 9Mg Application Accepted For Review By China's NMPA
25/11/2025 10:27
Nov 25 (Reuters) - Innovent Biologics Inc 1801.HK: MAZDUTIDE 9MG APPLICATION ACCEPTED FOR REVIEW BY CHINA'S NMPA Further company coverage: 1801.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis